InterventionsHuman trial

Integrated Diabetes Care Improves Metabolic Outcomes and Promotes Utilization of Incretin Analogs and Sodium–Glucose Cotransporter Type 2 Inhibitors in Patients with Serious Mental Illness

ADA Scientific Sessions 2025 Abstract

The paper

COMPAS F, MIEDLICH SU

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Late-breaking 2065-LB

doi.org/10.2337/db25-2065-lb

SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026